In this prospective nested case–control study, there were more patients with stage I and II CRC (I & II: III & IV = 2.08:1), and we found that the serum ITGB4 levels of stage III and IV CRC patients were higher than those of stage I and II CRC patients. Here, ITGB4 is linked to colorectal carcinoma.